Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 99
- Registration Number
- NCT06975722
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 192
- Registration Number
- NCT06975865
- Locations
- 🇬🇧
Investigational Site Number : 8260002, London, London, City Of, United Kingdom
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- Conditions
- Pneumococcal ImmunizationHealthy Volunteers
- Interventions
- Biological: PCV21 vaccineBiological: Vaxneuvance vaccineBiological: Hexyon vaccineBiological: M-M-RvaxPro vaccineBiological: Varivax vaccine
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1080
- Registration Number
- NCT06975878
- Locations
- 🇫🇮
Investigational Site Number : 2460008, Espoo, Finland
🇫🇮Investigational Site Number : 2460003, Kokkola, Finland
🇫🇮Investigational Site Number : 2460004, Oulu, Finland
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
- Conditions
- Polyneuropathy, Inflammatory Demyelinating, Chronic
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT06968975
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 99
- Registration Number
- NCT06958536
A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3
- Registration Number
- NCT06949358
- Locations
- 🇫🇷
Investigational Site Number : 2500002, Bron, France
🇫🇷Investigational Site Number : 2500001, Paris, France
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 35
- Registration Number
- NCT06941870
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- First Posted Date
- 2025-04-07
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 64
- Registration Number
- NCT06914908
- Locations
- 🇺🇸
Modena Allergy + Asthma- Site Number : 8400005, La Jolla, California, United States
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
- Conditions
- Pandemic Influenza ImmunizationHealthy Volunteers
- Interventions
- Biological: Pandemic flu H5 HA mRNA SD2 vaccineOther: Placebo
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT06907511
- Locations
- 🇺🇸
Velocity Clinical Research - San Diego- Site Number : 8400013, La Mesa, California, United States
🇺🇸Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400002, DeLand, Florida, United States
🇺🇸Accel Research Sites - Lakeland Clinical Research Unit- Site Number : 8400006, Lakeland, Florida, United States
A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
- Conditions
- Healthy VolunteersInfluenza VaccinationRespiratory Syncytial Virus VaccinationParainfluenza VaccinationHuman Metapneumovirus Vaccination
- Interventions
- Biological: TIV-HA formulation 1 at high doseBiological: TIV-HA formulation 2 at high doseBiological: TIV-HA Vaccine formulation 1 at low doseBiological: TIV-HA formulation 2 at low doseBiological: RSV/hMPV/PIV3 formulation 1 at high doseBiological: RSV/hMPV/PIV3 formulation 2 at high doseBiological: RSV/hMPV/PIV3 formulation 1 at low doseBiological: RSV/hMPV/PIV3 formulation 2 at low doseBiological: RIV4 (Supemtek®)
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 270
- Registration Number
- NCT06850051
- Locations
- 🇦🇺
University of Sunshine Coast Clinical Trials, South Brisbane, Queensland, Australia
🇦🇺Griffith University, Southport, Queensland, Australia
🇦🇺Emeritus Research, Camberwell, Victoria, Australia